Translational Science by Public Biotechnology Companies in the IPO“Class of 2000”: The Impact of Technological Maturity

por McNamee, Laura, Ledley, Fred
Publicado 2013

Modeling timelines for translational science in cancer; the impact of technological maturation

por McNamee, Laura M., Ledley, Fred D.
Publicado 2017

Timelines of translational science: From technology initiation to FDA approval

por McNamee, Laura M., Walsh, Michael Jay, Ledley, Fred D.
Publicado 2017

As Technologies for Nucleotide Therapeutics Mature, Products Emerge

por Beierlein, Jennifer M., McNamee, Laura M., Ledley, Fred D.
Publicado 2017

Contribution of NIH funding to new drug approvals 2010–2016

por Galkina Cleary, Ekaterina, Beierlein, Jennifer M., Khanuja, Navleen Surjit, McNamee, Laura M., Ledley, Fred D.
Publicado 2018

Comparing long-term value creation after biotech and non-biotech IPOs, 1997–2016

por Cleary, Ekaterina Galkina, McNamee, Laura M., de Boer, Skyler, Holden, Jeremy, Fitzgerald, Liam, Ledley, Fred D.
Publicado 2021